Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson's disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study

Authors

Jason Aldred, Selkirk Neurology and Inland Northwest Research
Susan R Criswell, Washington University School of Medicine in St. Louis
et al.

Journal

Neurology and Therapy

Publication Date

12-1-2023

Volume

12

Issue

6

First Page

1937

Last Page

1958

Document Type

Open Access Publication

DOI

10.1007/s40120-023-00533-1

Rights and Permissions

Aldred, J., Freire-Alvarez, E., Amelin, A.V. et al. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurol Ther 12, 1937–1958 (2023). https://doi.org/10.1007/s40120-023-00533-1 This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Aldred, Jason; Criswell, Susan R; and et al., "Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson's disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study." Neurology and Therapy. 12, 6. 1937 - 1958. (2023).
https://digitalcommons.wustl.edu/oa_4/2842

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.